# Quinuclidine derivatives.

## Abstract
Compounds of formula I , and pharmaceutically acceptable salts thereof CHEM wherein R1 is C1 6 alkyl R2 is amino, C1 7 acylamino or methyl R3 is halo or C1 6 alkylthio R4 and R5 are independently selected from hydrogen, C1 6 alkyl, phenyl or phenyl C1 4 alkyl any of which phenyl moieties may be substituted by one or two of halo, CF3, C1 6 alkoxy or C1 6 alkyl and n is 1 to 3 having gastric motility enchancing activity, a process for their preparation and their use as pharmaceuticals.

## Claims
Claims 1. A compound of formula I , or a pharmaceutically acceptable salt thereof EMI16.1 wherein R1 is C16 alkyl R2 is amino, C1 7 acylamino or methyl R3 is halo or C16 alkylthio R4 and R5 are independently selected from hydrogen, C16 alkyl, phenyl or phenyl C1 4 alkyl any of which phenyl moieties may be substituted by one or two of halo, CF3, C16 alkoxy or C1 6 alkyl and n is 1 to 3. 2. A compound according to claim 1 wherein R1 is methyl 3. A compound according to claim I or 2 wherein R3 is chloro or bromo. 4. A compound according to claim 1, 2 or 3 whereinR5 is hydrogen. 5. A compound according to claim 1 of formula II EMI17.1 wherein R6 is hydrogen or acetyl R41 is hydrogen or C16 alkyl and n is as defined in claim 1. 6. A compound according to any one of claims 1 to 5 wherein n is 2. 7. 4 Amino 5 chloro 2 methoxy N 4 quinuclidinyl benzamide. 8. A process for the preparation of a compound of formula I as defined in claim 1, which process comprises reacting a compound of formula III EMI17.2 with a compound of formula IV EMI18.1 wherein Q is a leaving group R7 is R2 or nitro and the remaining variables are as defined in claim 1. and thereafter optionally converting R7 to R2 apd or forming a pharmaceutically acceptable salt. 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. 10. A compound according to any one of claims 1 to 7 for use in the treatment of disorders relating to impaired gastro intestinal motility and or emesis.

## Description
NOVEL COMPOUNDSThis invention relates to substituted benzamides having pharmacological activity, to a process for their preparation and to their use as pharmaceuticals.U.K. Patent Application GB 2125398A discloses benzamides and benzoates having a quinuclidinyl side chain, especially 3 quinuclidinyl, and having serotonin M antagonist activity. EP A 99789 disclosesN 3 quinuclidinyl benzamides having gastro intestinal motility enhancing activity.A group of compounds have now been discovered which are 4 quinuclidinyl and related benzamides which compounds have good gastro intestinal motility enhancing activity and also anti emetic activity.Accordingly, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof EMI1.1 wherein R1 is C1 6 alkyl R2 is amino, C17 acylamino or methyl R3 is halo or C16 alkylthio R4 and R5 are independently selected from hydrogen, C16 alkyl, phenyl or phenyl C14 alkyl any of which phenyl moieties may be substituted by one or two of halo,CF3, C16 alkoxy or C16 alkyl and n is 1 to 3.Examples of R1 include methyl, ethyl, n and iso propyl. Preferably R1 is methyl.Examples of R2 include amino and C1 6 alkanoylamino, such as formylamino, acetylamino, propionylamino, ri and iso butyrylamino and methyl. Often R2 is amino or acetylamino, preferably amino.Examples of R3 include chloro, bromo, fluoro, methylthio, ethylthio, n and iso propylthio.Preferably R3 is chloro or bromo, most preferably chloro.Examples of R4 and R5 include hydrogen, methyl, ethyl, n and iso propyl, n , iso , sec and tert butyl, and phenyl, benzyl or phenethyl wherein any phenyl moiety is optionally substituted by one or two of chloro, bromo, fluoro, CF3, methoxy, ethoxy, n or iso propoxy, methyl, ethyl, n and iso propyl. Preferably R4 is hydrogen or methyl, often hydrogen, and R5 is hydrogen.n may be 1, 2 or 3, preferably 2. The pharmaceutically acceptable salts of the compounds of the formula I include acid addition salts with conventional acids such as hydrochloric, hydrobromic, boric, phosphoric, sulphuric acids and pharmaceutically acceptable organic acids such as acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulphonic, a keto glutaric, glycerophosphoric, and glucose l phosphoric acids.The pharmaceutically acceptable salts of the compounds of the formula I are usually acid addition salts with acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.Preferably the acid addition salt is the hydrochloride salt.Examples of pharmaceutically acceptable salts also include quaternary derivatives of the compounds of formula 1 include the compounds quaternised by compounds such as Rlo T wherein R10 is C16 alkyl, phenyl C1,6 alkyl or C57 cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of R10 include methyl, ethyl and n and iso propyl and benzyl and phenethyl. Suitable examples of T include halide such as chloride, bromide and iodide.Pharmaceutically acceptable salts of the compounds of formula I also include pharmaceutically acceptableN oxides.The compounds of the formula I , and their pharmaceutically acceptable salts, including quaternary derivatives and N oxides may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever compounds of formula I and salts thereof are herein referred to. it will of course be realised that some of the compounds of the formula I have chiral or prochiral centres and thus are capable of existing in a number of stereolsomeric forms including enantiomers. The invention extends to each of these stereoisomeric forms including enantiomers , and to mixtures thereof including racemates . The different stereoisomeric forms may be separated one from the other by the usual methods.A group of compounds within formula I is of formula 11 EMI4.1 wherein R6 is hydrogen or acetyl R41 is hydrogen or C16 alkyl and n is as defined in formula I .Examples and preferred values of the variable groups are as described for the corresponding groups under formula I .The invention also provides a process for the preparation of a compound of formula I , or a pharmaceutically acceptable salt thereof which process comprises reacting a compound of formula III EMI5.1 with a compound of formula IV EMI5.2 wherein Q is a leaving group R7 is R2 or nitro and the remaining variables are as hereinbefore defined, and thereafter optionally converting R7 to R2 and or forming a pharmaceutically acceptable salt.Examples of leaving groups Q, displaceable by a nucleophile include halogen such as chloro and bromo, hydroxy, carboxylic acyloxy such as C14 alkanoyloxy orC1 4 alkoxycarbonyloxy and activated hydrocarbyloxy such as pentacillorophenoxy. If a group Q is a halide, then the reaction is preferably carried out at non extreme temperatures in an inert non hydroxylic solvent, such as benzene, dichloromethane, toluene, diethyl ether, tetrahydrofuran THF or dimethylformamide DMF . It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as the solvent. Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate.Temperatures of 00 1000C, in particular 10 80 C are suitable.If a group Q is hydroxy, then the reaction is generally carried out in an inert non hydroxylic solvent, such as dichloromethane, THF or DMF optionally in the presence of a dehydrating catalyst, such as a carbodiimide, for example dicyclohexylcarbodiimide. When Y is CO the compound of formula IV is preferably in the form of an acid addition salt, such as the hydrohalide, for example the hydrochloride. The reaction may be carried out at any non extreme temperature, such as 10 to 1000C, for example, 0 to 800C. Generally, higher reaction temperatures are employed with less active compounds whereas lower temperatures are employed with the more active compounds.If a group Q is carboxylic acyloxy, then the reaction is preferably carried in substantially the same manner as the reaction when Q1 is halide. Suitable examples of acyloxy leaving groups include C14 alkanoyloxy and C14 alkoxycarbonyloxy, in which case the reaction is preferably carried out in an inert solvent, such as methylene chloride, at a non extreme teEperature for example ambient temperatures in the presence of an acid acceptor, such as triethylamine. C14 alkoxycarbonyloxy leaving groups may be generated in situ by treatment of the corresponding compound wherein Q1. is hydroxy with a C14 alkyl chloroformate. If a group Q is activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It is also preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried out at ambient temperature.Pharmaceutically acceptable salts of the compounds of this invention may be formed conventionally.The salts may be formed for example by reaction of the base compound of formula I with a pharmaceutically acceptable organic or inorganic acid.An R7 group may be converted to an amino group by reduction an R7 C17 acylamino substituent is convertible to an amino substituent by deacylation, and an amino substituent is convertible to a C17 acylamino substituent by acylation with a carboxylic acid derivative. The reduction is carried out with a reagent suitable for reducing nitroanisole to aminoanisole deacylation is carried out by treatment with a base such as an alkali metal hydroxide acylation is carried out using, for example the corresponding acid chloride or free acid if formylation is to be carried out.Compounds of the formulae III and IV are known or are preparable analogously to, or routinely from, known compounds. Compounds of formula IV may be prepared in the manner described by H.P. Fischer and C.A. Grob,Helv. Chim. Acta 51, 153, 1968.Compounds of the present invention have gastro intestinal motility enhancing activity and therefore may be used in disorders such as retarded gastric emptying, dyspepsia, flatulence, oesophagal reflux and peptic ulcer. The compounds of the present invention also have anti emetic activity. T invention also provides a pharmaceutical composition comprising a compound of formula I , or a ptnu ct ut√¨cally acceptable salt thereof, and a phcYl,2ceutically acceptable carrier.Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with an enteric coating.Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents , for example lecithin, sorbitan monooleate, or acacia non aqueous vehicles which may include edible oils , for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol preservatives, for example methyl or propyl p hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non aqueous vehicles which may include edible oils , preservatives, and flavouring or colouring agents.The oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art. For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicles Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution Of the compound of the invention.The invention further provides a method of treatment or. prophylaxis of disorders relating to impaired gastro intestinal motility and or emesis in mammals, such as humans, which comprises the administration of an effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose for a 70kg adult will normally contain 0.5 to 1000mg for example 1 to 500mg, of the compound of the invention. Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.001 to 50 mg kg day, more usually 0.002 to 25 mg kg day. No adverse toxicological effects are indicated at any of the aforementioned dosage ranges.The invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatmentof isorders relating to impaired gastro intestinal motility and or emesis.The following Example illustrates the preparation of compounds offormula I the following description relates to the preparation of an intermediate. Description 1 4 Aminoquinuclidine D.1 EMI12.1 A suspension of quinuclidine 4 carboxylic acid 3.0g in thionyl chloride 20ml was heated on a steam bath for 2h. The excess thionyl chloride was removed by rotary evaporation and the residue re evaporated with xylene 2 x 5Om1 The residue was stirred with an ice cold solution of sodium azide 5.Og in water 50ml for 10 min, basified with solid K2C03 and the acyl azide extracted into ether 3 x 50n1 and dried Na2S04 . The filtered solution was carefully evaporated to dryness in vacuo and the residue heated to reflux in dry toluene lOOml for 30 min. The so formed isocyanate was extracted into 5NHC1 50ml and heated to reflux for lh.The aqueous reaction mixture was concentrated in vacuo and the residue treated with saturated K2C03 solution. The product was extracted into CH2C12 containing 58 ethanol 3 x dried K2C03 and evaporation gave the crude 4 aminoquinuclidine 1.5g which was used without further purification. Example 1 4 Amino 5 chloro 2 methoxy N 4 quinuclidinyl benzamide El EMI13.1 A suspension of 4 acetamido 5 chloro 2methoxybenzoic acid 2.9g in dry CH2C12 lOOml was treated with oxalyl chloride l.Oml and DMF 5 drops and stirred at room temperature for lh. A solution of 4 aminoquinuclidine 1.5g in CH2C12 50ml followed by triethylamine 5ml was then added and the whole stirred at room temperature for Zh. The CH2Ci2 solution was washed with 10 Na2C03 solution 100m1 , dried K2C03 , evaporated to dryness and the residue triturated with Et20 to afford the acetamido derivative of El 3.7g .A solution of the acetamido derivative 3.7g in EtOH 100ml was treated with 10 NaOH solution l0ml and heated under reflux for lh. On cooling, the solvent was removed by rotary evaporation and the residue extracted with CHC13 200ml . The CHC13 extracts were dried K2C03 , evaporated to dryness and the residue recrystallised CH2Cl2 EtOAc petrol to give El 1.7g mp 275 80 dex 1H NMR 79.5MHz, d6 DMSO CDCl3 6 7.88 1H, s 7.51 1H, brs 6.50 1H, s 5.30 2H, brs 3.90 3H, s 2.95 6H, dd 1.94 6H, dd Pharmacological DataIntragastric pressure in the ratIntragastric pressure changes were recorded from fasted conscious and restrained rats using a saline filled catheter inserted into the lumen of the stomach via a permanent gastric fistula. The catheter was connected to a physiological pressure transducer and pressure changes recorded on a hot wire pen recorder. An index of activity was obtained by measuring the average height of pressure waves during 10 minute periods. Values for 4 such periods were obtained during assessment of spontaneous activity prior to dosing and or the 40 minute period following dosing with compound or vehicle. The Student s t test was applied to the mean values obtained for activity prior to and post treatment. Groups of 10 animals were used for each treatment.The compound of Example 1 was active at a dose of 0.5 mg kg s.c.